60 DEGREES PHARMACEUTICALS, INC. 8-KCurrent Reports (8-K / ad hoc)

Business

Item 1.01 Entry into a Material Definitive Agreement On July 30, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell in a private placement offering (the “Private Placement”) an aggregate of (i) 191,571 shares of its common stock, par value $0.0001 per share (the “Common Stock”) at a purchase price of $1.74 per share and associated Common Warrants (as defined below), (ii) pre-funded warrants to purchase up to 383,142 shares of Common Stock (the “Pre-funded Warrants”) at a purchase price of $1.739 per Pre-funded Warrant and associated Common Warrants, (iii) series A warrants to purchase up to 574,413 shares of Common Stock (“Series A Warrants”) and (iv) series B warrants to purchase up to 574,413 shares of Common Stock (“Series B Warrants” and, collectively with Series A Warrants, the “Common Warrants”) at a combined per share purchase price of $1.74 per share, provided that the purchase price per Pre-funded Warrant was the per share purchase price minus $0.001, for gross proceeds of approximately $1.0 million, before the deduction of placement agent fees and offering expenses. The closing of the Private Placement occurred on July 31, 2026. The Pre-funded Warrants were sold, at the Purchaser’s election, to such Purchaser whose purchase of shares of Common Stock in the Private Placement would otherwise result in such Purchaser, together with its affiliates and certain related parties, beneficially own more than 4.99% (or, at such Purchaser’s option upon issuance 9.99%) of the Company’s outstanding Common Stock immediately following the consummation of the Private Placement. The Pre-Funded Warrants have an exercise price of $0.001 per share, will become exercisable upon issuance and remain exercisable until exercised in full. The Common Warrants have an exercise price of $1.49 per share and will be exercisable from the date of issuance. The Series A Warrants will expire five (5) years from the effective date of the registration statement covering the resale of the shares issuable upon exercise of thereof (the “Effective Date”) and the Series B Warrants will expire twenty-four (24) months from the Effective Date. A holder of a Common Warrant or Pre-funded Warrant will not have t